A new male contraceptive is showing promising results in the early stages of human clinical trials, meaning it could launch a new era of reproductive technologies.

“I think we as a society, especially younger men, millennials, are realizing that we need to change the overbearing reliance on women as a whole as the main users of contraception and family planning,” said Kevin Eisenfrats, the CEO and co-founder of the start-up Contraline, which is developing the contraceptive.